Literature DB >> 1663226

Morphine differentially affects the sensory and affective pain ratings in neurogenic and idiopathic forms of pain.

Ron C Kupers1, Herman Konings, Hugo Adriaensen, Jan M Gybels.   

Abstract

In a double-blind, placebo controlled crossover study, the effect of morphine on the affective and sensory pain ratings in different forms of chronic pain was investigated. Six patients suffering from central neurogenic pain, 8 from peripheral neurogenic pain and 6 from idiopathic pain participated in the study. Morphine (0.3 mg/kg bodyweight) and placebo (saline) were administered intravenously. Both the affective and sensory dimensions of pain sensation were assessed by means of the 101-point rating scale. From our results it appeared that morphine reduced the affective but not the sensory dimension of pain sensation in both groups of neurogenic pain patients. In the idiopathic pain group, neither the affective nor the sensory dimension of pain sensation were affected. The observed differences in opioid responsiveness were neither the result of differences in opioid consumption nor of differences in baseline pain levels.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1663226     DOI: 10.1016/0304-3959(91)90004-H

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  29 in total

1.  Use of opioids to treat chronic, noncancer pain.

Authors:  B D Dickinson; R D Altman; N H Nielsen; M A Williams
Journal:  West J Med       Date:  2000-02

2.  DAMGO in the central amygdala alleviates the affective dimension of pain in a rat model of inflammatory hyperalgesia.

Authors:  R-X Zhang; M Zhang; A Li; L Pan; B M Berman; K Ren; L Lao
Journal:  Neuroscience       Date:  2013-08-28       Impact factor: 3.590

3.  Nerve Injury Diminishes Opioid Analgesia through Lysine Methyltransferase-mediated Transcriptional Repression of μ-Opioid Receptors in Primary Sensory Neurons.

Authors:  Yuhao Zhang; Shao-Rui Chen; Geoffroy Laumet; Hong Chen; Hui-Lin Pan
Journal:  J Biol Chem       Date:  2016-02-25       Impact factor: 5.157

4.  Can a pharmacological pain analysis be used in the assessment of chronic low back pain?

Authors:  J Sörensen; S Kalman; H Tropp; M Bengtsson
Journal:  Eur Spine J       Date:  1996       Impact factor: 3.134

5.  Endogenous opioid activity in the anterior cingulate cortex is required for relief of pain.

Authors:  Edita Navratilova; Jennifer Yanhua Xie; Diana Meske; Chaoling Qu; Kozo Morimura; Alec Okun; Naohisa Arakawa; Michael Ossipov; Howard L Fields; Frank Porreca
Journal:  J Neurosci       Date:  2015-05-06       Impact factor: 6.167

6.  Midazolam exacerbates morphine tolerance and morphine-induced hyperactive behaviors in young rats with burn injury.

Authors:  Li Song; Shuxing Wang; Yunxia Zuo; Lucy Chen; Jeevendra A Martyn; Jianren Mao
Journal:  Brain Res       Date:  2014-04-05       Impact factor: 3.252

7.  Specifying the non-specific factors underlying opioid analgesia: expectancy, attention, and affect.

Authors:  Lauren Y Atlas; Joseph Wielgosz; Robert A Whittington; Tor D Wager
Journal:  Psychopharmacology (Berl)       Date:  2013-10-06       Impact factor: 4.530

Review 8.  Challenges in the development of novel treatment strategies for neuropathic pain.

Authors:  Michael H Ossipov; Frank Porreca
Journal:  NeuroRx       Date:  2005-10

9.  Cerebral responses to pain in patients with atypical facial pain measured by positron emission tomography.

Authors:  S W Derbyshire; A K Jones; P Devani; K J Friston; C Feinmann; M Harris; S Pearce; J D Watson; R S Frackowiak
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-10       Impact factor: 10.154

10.  The absence of endogenous beta-endorphin selectively blocks phosphorylation and desensitization of mu opioid receptors following partial sciatic nerve ligation.

Authors:  M Petraschka; S Li; T L Gilbert; R E Westenbroek; M R Bruchas; S Schreiber; J Lowe; M J Low; J E Pintar; C Chavkin
Journal:  Neuroscience       Date:  2007-04-30       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.